GTHT Securities has raised its target price for 3SBIO (01530) to HK$47.84 (from HK$46.71) while maintaining an "Overweight" rating. The upgrade reflects the company's strong fundamentals and the significant potential of its PD(L)1/VEGF pipeline. The firm believes 3SBIO's spin-off of Mindy International will benefit shareholders of both entities, allowing 3SBIO to focus on innovative drug development while Mindy concentrates on consumer healthcare products.

Key insights from GTHT Securities include: 1. **Value Recognition**: The spin-off will better reflect Mindy International's intrinsic value. Through a distribution-in-kind, existing 3SBIO shareholders will retain stakes in both the remaining group's growth and Mindy's expansion. 2. **Business Advantages**: Mindy International specializes in skin health and weight management solutions. The separation will enhance its brand recognition among clients, suppliers, and potential partners, facilitating business negotiations and expansion. 3. **Financial Flexibility**: The move will improve financial flexibility for both companies and strengthen their ability to maintain stable cash flows for sustainable growth.

**Mindy's Growth Potential**: As China's leading consumer healthcare company, Mindy has established market leadership in hair health solutions. Its flagship Minoxidil-based hair loss treatment has dominated China's anti-hair loss drug market since 2014, holding 57% and 71% market shares in 2024 for the overall hair loss treatment and Minoxidil segments respectively. The company is expanding into broader skin health and weight management areas to meet growing consumer demand.

**Financial Performance**: Mindy International demonstrated consistent growth from 2022-2024: - Revenue: RMB982 million (2022), RMB1.228 billion (2023), RMB1.455 billion (2024) - 21.7% CAGR - Gross Margins: 80.3%, 82.0%, 82.7% - Net Profit: RMB202 million, RMB341 million, RMB390 million - Net Margins: 20.5%, 27.8%, 26.8%

**Risk Factors**: Potential unsuccessful spin-off, slower-than-expected R&D progress, political risks, underperforming drug sales, policy changes, industry risks, and other uncertainties.